Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Atenolol
AstraZeneca UK Limited
C07AB; C07AB03
Atenolol
25 milligram(s)
Film-coated tablet
Product subject to prescription which may be renewed (B)
Beta blocking agents, selective; atenolol
Marketed
1992-08-14
BODY TEXT SIZE 12.0 pt SMALLEST TEXT SIZE 6.0 pt 552958-A02 14-04-17 P043470 630170L4 564 AN Atenolol 25mg, 50mg, 100mg Leaflet: Combined IE-MT Black Technical Info Profile Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. In this leaflet: 1. What Tenormin is and what it is used for 2. What you need to know before you take Tenormin 3. How to take Tenormin 4. Possible side effects 5. How to store Tenormin 6. Contents of the pack and other information 1. What Tenormin is and what it is used for Tenormin contains a medicine called atenolol. This belongs to a group of medicines called beta‑blockers. Tenormin is used to: • Treat high blood pressure (hypertension). • Help prevent chest pain (angina). • Treat uneven heart beats (arrhythmias). • Protect the heart in the early treatment after a heart attack (myocardial infarction). • Help prevent another heart attack from happening. It works by making your heart beat more slowly and with less force. 2. What you need to know before you take Tenormin Do not take Tenormin: • If you are allergic to atenolol or any of the other ingredients of this medicine (listed in section 6). • If you have ever had any of the following heart problems: ‑ heart failure which is not under control (this usually makes you breathless and causes your ankles to swell) ‑ second‑ or third‑degree heart block (a condition which may be treated by a pacemaker) ‑ very slow or very uneven heart beats, very low blood pressure or very poor circulation. • If you have a tumour called phaeoc Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tenormin 25 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25 mg Atenolol. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet White, round, biconvex, film-coated tablets, which are intagliated with 25 on one face and plain on the reverse face. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Control of hypertension. Management of angina pectoris. Control of cardiac arrhythmias. In early intervention in the acute phase of myocardial infarction and for long-term prophylaxis after recovery from myocardial infarction. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY ADULTS CONTROL OF HYPERTENSION: Most patients respond to 50 mg daily given orally as a single dose. If necessary, the dose may be increased to 100 mg daily. The effect will be fully established after one to two weeks. A further reduction in blood pressure may be achieved by combining Tenormin 25 mg with other antihypertensive agents. MANAGEMENT OF ANGINA PECTORIS: Most patients with angina pectoris will respond to 100 mg daily given orally as a single dose or as 50 mg given twice a day. It is unlikely that additional benefit will be gained by increasing the dose. CONTROL OF CARDIAC ARRHYTHMIAS: An oral maintenance dose of Tenormin is 50–100 mg, given once daily. EARLY AND LATE INTERVENTION AFTER MYOCARDIAL INFARCTION: Oral treatment with Tenormin can be initiated in haemodynamically stable patients with 50 mg twice daily, and then 100 mg once daily. During the early phase of acute myocardial infarction, treatment with Tenormin should be initiated in hospital under close monitoring. If bradycardia and/or hypotension requiring treatment, or any other untoward effects occur, Tenormin should be discontinued. Tenormin 100 mg daily is recommended for long-term prophylaxis of myocardial infarction. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _ Read the complete document